Business Wire - Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
October 15, 2008 -- CAMBRIDGE, Mass. -- Genzyme Corporation (Nasdaq: GENZ) announced today that the company has begun enrollment in a world-wide post-marketing clinical...
Journal of Drugs in Dermatology - Genzyme completes phase IV study of Fabrazyme for Fabry's disease
November 1, 2004 -- Genzyme has successfully completed its principal Phase IV study of Fabrazyme (recombinant alpha galactosidase beta) and performed a preliminary...
Transplant News - Genzyme updates timeframe for acquisition of ILEX Oncology; completes Phase 4 Fabrazyme study
September 30, 2004 -- Genzyme Corporation, Cambridge, MA, and ILEX Oncology, San Antonio, TX, announced the company is continuing to have product discussions with the US...
Pharma Marketletter - Update: Genzyme gets US go-ahead for Fabrazyme.
May 5, 2003 -- The US Food and Drug Administration has granted marketing approval to Genzyme for its Fabrazyme (agalsidase beta) enzyme replacement therapy for...
Pharma Marketletter - Genzyme gets US go-ahead for Fabry drug Fabrazyme.
May 5, 2003 -- The US Food and Drug Administration has granted marketing approval to Genzyme for its Fabrazyme (agalsidase beta) enzyme replacement therapy for...
Business Wire - Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect from April 2008
June 18, 2008 -- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the...
Chemical Market Reporter - Genyzme wins FDA nod. (News in Brief).(Genzyme Corp., U.S. Food and Drug Administration approval for marketing Fabrazyme )(Brief Article)
April 28, 2003 -- Genzyme Corp. has been granted Food and Drug Administration (FDA) approval to market Fabrazyme (agalsidase beta). The drug will be the first...
Business Wire - Zacks Broker Upgrades: Marvell, Genzyme, Praxair, Starwood Hotels
July 27, 2007 -- CHICAGO -- Studies have shown that broker upgrades lead to short-term outperformance. Stocks recently upgraded by brokerage analysts include Marvell...
Business Wire - Research and Markets: Benchmark Genzymes Performance against Key Rivals in the Ethical Pharmaceutical Sector - 'Genzyme: Pharmavitae Profile'
December 15, 2006 -- DUBLIN -- Research and Markets (http://www.researchandmarkets.com/reports/c47205) has announced the addition of Genzyme: PharmaVitae Profile to their...
Business Wire - Research and Markets: Genzyme's Inorganic Growth Path and Strategic Initiatives Are Explored Inside New Report
August 3, 2006 -- DUBLIN, Ireland -- The US biotech industry is highly diversified, complex and fragmented with as many as 14,370 units in operation. The industry is...
